Freeze-dried FSH/LH formulations

Details Freeze-dried FSH/LH formulations Freeze-dried FSH/LH formulations

2004-06-16

2010-06-22

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Particulate form

C514S002600, C514S008100, C514S023000, C424S198100, C530S313000

Reexamination Certificate

active

07740884

ABSTRACT:
The invention relates to the field of pharmaceutical formulations of a mixture of follicle stimulating hormone (FSH) and luteinising hormone (LH), and to methods of producing such formulations.

REFERENCES:
patent: 4496537 (1985-01-01), Kwan
patent: 4589402 (1986-05-01), Hodgen et al.
patent: 4659696 (1987-04-01), Hirai et al.
patent: 4670419 (1987-06-01), Uda et al.
patent: 4746508 (1988-05-01), Carey et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 5087615 (1992-02-01), Chappel
patent: 5128453 (1992-07-01), Arpaia et al.
patent: 5162306 (1992-11-01), Donaldson
patent: 5270057 (1993-12-01), de Meere et al.
patent: 5356876 (1994-10-01), Espey
patent: 5374620 (1994-12-01), Clark et al.
patent: 5384132 (1995-01-01), De Meere et al.
patent: 5508261 (1996-04-01), Moyle et al.
patent: 5580856 (1996-12-01), Prestrelski et al.
patent: 5639640 (1997-06-01), Reddy et al.
patent: 5650390 (1997-07-01), Samaritani et al.
patent: 5661125 (1997-08-01), Strickland
patent: 5681822 (1997-10-01), Bornstein et al.
patent: 5733572 (1998-03-01), Unger et al.
patent: 5767067 (1998-06-01), Arpaia et al.
patent: 5811096 (1998-09-01), Aleman et al.
patent: 5889110 (1999-03-01), Hutchinson et al.
patent: 5929028 (1999-07-01), Skrabanja et al.
patent: 5945187 (1999-08-01), Buch-Rasmussen et al.
patent: 6066620 (2000-05-01), McGregor et al.
patent: 6136784 (2000-10-01), L'Italien et al.
patent: 6238890 (2001-05-01), Boime et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 6440930 (2002-08-01), Rinella, Jr.
patent: 6541606 (2003-04-01), Margolin et al.
patent: 6573237 (2003-06-01), Rinella, Jr.
patent: 2003/0072803 (2003-04-01), Goldenberg et al.
patent: 2006/0241047 (2006-10-01), Hoffmann et al.
patent: 1340132 (1998-11-01), None
patent: 41 17 078 (1882-11-01), None
patent: 0 318 081 (1989-05-01), None
patent: 0 448 146 (1991-09-01), None
patent: 0 652 766 (1993-07-01), None
patent: 0 603 159 (1994-06-01), None
patent: 0 853 945 (1998-07-01), None
patent: 0 920 873 (1998-12-01), None
patent: 0 891 774 (1999-01-01), None
patent: 0 668 073 (1999-04-01), None
patent: 1 191 099 (1999-06-01), None
patent: 0 736 303 (1999-08-01), None
patent: 0 974 359 (2000-01-01), None
patent: 1176976 (2006-07-01), None
patent: 2782455 (2000-02-01), None
patent: 839300 (1958-08-01), None
patent: 1065127 (1967-04-01), None
patent: WO 92/21332 (1992-12-01), None
patent: WO 92/22568 (1992-12-01), None
patent: WO 93/11788 (1993-06-01), None
patent: WO 94/03198 (1994-02-01), None
patent: WO 97/04801 (1997-02-01), None
patent: WO 97/17087 (1997-05-01), None
patent: WO 98/30592 (1998-07-01), None
patent: WO 99/21534 (1999-05-01), None
patent: WO/00/67778 (2000-11-01), None
Observations by a third party concerning the patentability of the invention of EP application No. 04766052.7-2107 (EP1176976) dated Jan. 28, 2008.
Akers Michael J., “Considerations in selecting antimicrobial preservative agents for parenteral product development”, Pharmaceutical Technology, May 1984, pp. 36-46.
Akers, Michael J., “Excipient—Drug Interactions in Parenteral Formulations”, Journal of Pharmaceutical Sciences, Nov. 2002, vol. 91, No. 11, pp. 2283-2300.
Amir, Syed M. et al., “Phenol, A Potent Stimulator of Adenylate Cyclase in Human Thyroid Membranes”, Endocrine Research Communications, 8(2):83-95, 1981.
A.P.L.® Injection 5 000 IU and Injection 10 000 IU, http://home.intekom.com/pharm/akromed/apl-inj.html, Dec. 12, 2002, pp. 1-2.
Arzneiformenlehre, Paul Heinz List, Wissenschaftliche Verlagsgellschaft mbH, Stuttgart, 4th Edition, 1985, pp. 402-407.
Boime, Irving et al., “Glycoprotein Hormone Structure-Function and Analog Design”, Recent Progress in Hormone Research, vol. 54, 1999, The Endocrine Society, pp. 271-289.
Combarnous, Yves, “Molecular Basis of the Specificity of Binding of Glycoprotein Hormones to Their Receptors”, Endocrine Reviews, 1992. vol. 13, No. 4, pp. 670-691.
CPMP Guidelines antimicrobial preservative inclusion, CPMP/CVMP/OWP/115/95, Jul. 8, 1997, pp. 1-6.
de Medeiros, S.F. et al., “Stability of Immunoreative β-Core Fragment of hCG”, Obstetrics & Gynecology, vol. 77, No. 1, Jan. 1991, pp. 53-59.
Fransson, Jonas et al., “Solvent Effects on the Solubility and Physical Stability of Human Insulin-Like Growth Factor 1”, Pharmaceutical Research 14(5):606-12, 1997.
Frenken, L.A.M. et al., “Analysis of the Efficacy of Measures to Reduce Pain After Subcutaneous Administration of Epoetin Alfa”, Nephrology Dialysis Transplantation 9:1295-98, 1994.
Furuhashi, M. et al. “Fusing the Carboxy-Terminal Peptide of the Chorionic Gonadotropin (CG) beta Subunit to the Common alpha-Subunit: Retention of O-linked Glycosylation and Enhanced in Vivo Bioactivity of Chimeric Human CG”, Molecular Endocrinology, 1995, vol. 9, No. 1, pp. 54-63.
Garcia-Campayo, Vincenta et al., “Design of Stable Biologically Active Recombinant Lutropin Analogs”, Nature Biotechnology 15:663-67, 1997.
Gennaro et al., “Parenteral Preparations”, Chapter 84, Remington's Pharmaceutical Sciences (18th Edition, Mack Publishing. Co., 1990, see part 8 “Pharmaceutical Preparations and their Manufacture,” pp. 1545-1569.
Gonal-F® (follitropin alfa for injection) For subcutaneous injection: Package Insert Code N1900101B, manufactured by Serono Laboratories, Inc., Randolph, MA, USA, published Sep. 1997.
Harvey, Stewart C., “Antiseptics and Disinfectants; Fungicides; Ectoparasiticides”, The Pharmacological Basis of Therapeutics, 6thEdition, Chapter 41, 964-987, 1980.
Heikoop, Judith C. et al., “Structure-based design and protein engineering of intersubunit disulfide bonds in gonadotropins” Nature Biotechnology, Jul. 1997, vol. 15, pp. 658-662.
Package insert HRF, “HRF* Injection 0,1 mg and HRF* Injection 0,5 mg”, Malahyde Information Systems, 2003, pp. 1-4.
Jorgenson, Jan Trost, “Improvement of Patient Convenience in Treatment with Growth Hormone”, Journal of Pediatric Endocrinology, 1994, 7(2):175-180.
Kesner, J.S. et al., “Stability of Urinary Female Reproductive Hormones Stored Under Various Conditions”, Reproductive Toxicology, vol. 9, No. 3, pp. 239-244, 1995.
Lam, Xanthe M. et al., “The Effect of Benzyl Alcohol on Recombinant Human Interferon-γ” Pharmaceutical Research, 1997, vol. 14, No. 6, 725-729.
Leukine Package Insert/Approved Text, Rev. 0230-02, Issued Feb. 1998, pp. 1-30.
Livesey J. H. et al., “Glycerol prevents loss of immunoreactive follicle-stimulating hormone and luteinizing hormone from frozen urine”, Journal of Endocrinology, vol. 98, pp. 381-384, 1983.
Livesey, J. H. et al., “Effect of Time, Temperature and Freezing on the Stability of Immunoreative LH, FSH, TSH, Growth Hormone, Prolactin and Insulin in Plasma”, The Medical Unit, Princess Margaret Hospital, Christchurch 2, New Zealand, Jun. 25, 1980, Biochem 13 (4), 1980, pp. 151-155.
Maa, Yuh-Fun, et al., “Aggregation of recombinant human growth hormone induced by phenolic compounds”, International Journal of Pharmaceutics, 1996, vol. 140, pp. 155-168.
Pimpalkhute, M. et al., “Radioimmunoassay of Human Follicle Stimulating Hormone/HFSH/”, J. Radioanal. Nucl. Chem. Letters, 1986, 103, No. 2, pp. 105-116.
Pregnyl Prescribing Information, Pregnyl (chorionic gonadotropin for injection, USP), Organon Inc., Aug. 1998, pp. 1-4.
Profasi (chorionic gonadotropin for injection, USP) for intramuscular injection, Serono Laboratories, Inc. (revised Jun. 1993).
Rafferty, M.J. et al., “Safety and Tolerability of a Multidose Formulation of Epoetin Beta in Dialysis Patients”, Clinical Nephrology. 54(3):240-45, 2000.
Remmele Jr., Richard L. et al., “Interleukin-1 Receptor (IL-1R) Liquid Formulation Development Using Differential Scanning Calorimetry”, Pharmaceutical Research, 1998, vol. 15, No. 2 pp. 200-208.
Rose, M.P. et al, “Characterisation, calibration

Affiliated with

Also associated with

Rating

Freeze-dried FSH/LH formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Freeze-dried FSH/LH formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Freeze-dried FSH/LH formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4158704